Sabrina McCrear

New York City nurses continue their strike over staffing, safety, and benefits through negotiations on day 5 of the city’s largest nursing strike.

France approved botensilimab plus balstilimab for select ovarian cancers and soft tissue sarcomas, expanding early access to this dual immunotherapy.

With ACA subsidies in limbo, ICHRAs may reshape how Americans access coverage. Here are 5 FAQs explaining what they are, who benefits, and key trade-offs.

Poland’s LiBRha project will expand liquid biopsy and molecular testing nationwide to improve diagnosis, monitoring, and outcomes for children with soft tissue sarcoma.

Most workers are unprepared to shop for individual plans under ICHRAs, highlighting gaps in decision tools, guidance, and consumer protections.

ICHRAs could either stabilize or destabilize ACA risk pools, with adoption patterns raising concerns about access, equity, and coverage for sicker workers.

ED law enforcement interactions affect survivors of violence and immigrant patients, emphasizing training and advocacy.

Patients undergoing lung or colon cancer surgery at rural hospitals that later closed had better outcomes after transfer to high-performing oncology centers.

Social determinants of health influence heart failure and arrhythmia risk in HCM, highlighting the need for more holistic, equitable risk stratification.

Lower income and higher social deprivation were associated with increased heart failure and arrhythmia risk in patients with hypertrophic cardiomyopathy.

Genetic and metabolic differences may increase aggressive early breast cancer risk in Latin American women with obesity, notes William Audeh, MD, MS.

A meta-analysis found β-blockers did not improve clinical outcomes in patients with acute MI and preserved LVEF, raising questions about routine use.

Nimbus Therapeutics and Eli Lilly announce their partnership to develop a novel oral drug for patients with obesity and other metabolic disorders.

Findings from SABCS genetic differences between Latin American and non-Hispanic White women with breast cancer and h

Sachin H. Jain, MD, MBA, discusses 2026 health care predictions, including AI adoption, GLP-1 demand, MAHA growth, DEI’s return, and policy shifts.

Our top 5 obesity articles of 2025 highlight GLP-1 prescribing trends, insurance coverage, co-pay caps, real-world use, and access challenges.

New therapies and individualized care plans for menopausal women highlighted the most-read 2025 SABCS coverage.

Our top dermatology content of 2025 highlights AI wearables, new biologics, emerging vitiligo treatments, and strategies for rare and complex skin diseases.

Here are our top highlights from AAD 2025 that include safety of topical JAK inhibitors, climate impacts on skin health, affordability of classic therapies, and advancing AI in dermatology.

Our top 5 heart failure content of 2025 include FDA approvals, GDMT optimization, risk markers like LBBB and SDOH, and value-based care models improving outcomes in heart failure.

Heart failure deaths increasingly occur at home or in hospice, but racial, sex, and regional disparities persist in end-of-life care.

ASCO 2025 highlighted breakthroughs, including improved cancer survival in key trials, new AI guideline tools, and expanding GLP-1 cancer research.

Martha Gulati, MD, explains how bias and underrepresentation in research lead to misdiagnosis of HFpEF in women and delays in care.

The top Managed Care Cast episodes explored wellness visits, weight loss drug access, neurospine care, public health policy, and ketamine-assisted therapy.

A phase 2b trial found vixarelimab rapidly reduced itch and lesion burden in prurigo nodularis, with sustained benefit and a favorable safety profile.

A study using Mendelian randomization found higher BMI and IBD have causal links to hidradenitis suppurativa risk.

A novel phase 1 trial explores the safety and efficacy of targeted radiotherapy for leptomeningeal metastases in breast cancer patients.

A new study finds patients with unmet social needs like housing or transportation face higher ED and inpatient use and that resolving these needs may reduce utilization.

With ACA subsidies expiring, experts warn coverage losses could worsen access to behavioral health care and emergency department strains.

The FDA approved trastuzumab deruxtecan plus pertuzumab for first-line HER2-positive metastatic breast cancer after DESTINY-Breast09 showed major PFS gains.